CD8A and neoplasm: Moreover, B16-OVA tumour-bearing mice treated with asparaginase before the transfer of tumour-specific OT-1 CD8+ T cells, completely impede tumour growth (Extended Data Fig. 2b), highlighting that the quality of tumour-reactive CD8+ T cells can be modulated in response to asparaginase treatment.